Beyond Diuretics: Management of Volume Overload in Acute Heart Failure Syndromes

American Journal of Medicine

Volumn 119, Issue 12 SUPPL., 2006, Pages

  Hill, James A ^a   Yancy, Clyde W ^b   Abraham, William T ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Diuretics; Heart failure; Inotropes; Treatment; Vasodilators

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CALCIUM SENSITIZER; DENDROASPIS NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NAXIFYLLINE; NESIRITIDE; NITROPRUSSIDE SODIUM; TOLVAPTAN; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; DIURESIS; DIURETIC THERAPY; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; GLOMERULAR DYSFUNCTION; HEART ARRHYTHMIA; HUMAN; HYPERVOLEMIA; HYPOTENSION; KIDNEY INJURY; MORBIDITY; MORTALITY; NATRIURESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRAFILTRATION; UREMIA;

ACUTE DISEASE; BLOOD VOLUME; CARDIOTONIC AGENTS; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; SYNDROME; ULTRAFILTRATION; VASODILATOR AGENTS; WATER-ELECTROLYTE BALANCE;

EID: 33750943349     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.09.015     Document Type: Article

References (79)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in J Am Coll Cardiol. 2006;47:1503-1505]. J Am Coll Cardiol 46 (2005) e1-e82
2. Nieminen M.S., Böhm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
3. DiDomenico R.J., Park H.Y., Southworth M.R., et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 38 (2004) 649-660
4. Gupta S., and Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 26 (2005) 644-649
5. Sackner-Bernstein J.D. Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure. Curr Cardiol Rep 7 (2005) 204-210
6. Fonarow G.C. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Failure Rev 9 (2004) 179-185
7. Cody R.J. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 22 suppl A (1993) 165A-171A
8. Agostoni P., Marenzi G., Lauri G., et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 96 (1994) 191-199
9. Bayliss J., Norell M., Canepa-Anson R., Sutton G., and Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57 (1987) 17-22
10. Costello-Boerrigter L.C., Boerrigter G., and Burnett Jr. J.C. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am 87 (2003) 475-491
11. Ikram H., Chan W., Espiner E.A., and Nicholls M.G. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 59 (1980) 443-449
12. Kubo S.H., Clark M., Laragh J.H., Borer J.S., and Cody R.J. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol 60 (1987) 1322-1328
13. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., and Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 103 (1985) 1-6
14. Brater D.C. Diuretic therapy. N Engl J Med 339 (1998) 387-395
15. Ellison D.H. Diuretic resistance: physiology and therapeutics. Semin Nephrol 19 (1999) 581-597
16. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
17. Anderson K.P. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann Noninvasive Electrocardiol 8 (2003) 75-89
18. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
19. Cotter G., Weissgarten J., Metzkor E., et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 62 (1997) 187-193
20. Dormans T.P.J., van Meyel J.J.M., Gerlag P.G.G., Tan Y., Russel F.G.M., and Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28 (1996) 376-382
21. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
22. Schuller D., Lynch J.P., and Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 25 (1997) 1969-1975
23. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
24. Smith G.L., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 9 (2003) 13-25
25. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., Boscardin W.J., ADHERE Scientific Advisory Committee, Study Group, and and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
26. Wright S.P., Verouhis D., Gamble G., Swedberg K., Sharpe N., and Doughty R.N. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail 5 (2003) 201-209
27. Singh A., Blackwell J., and Neher J. Does furosemide decrease morbidity or mortality for patients with diastolic or systolic dysfunction? [clinical inquiries]. J Fam Pract 54 (2005) 370-372
28. Mehta R.L., Pascual M.T., Soroko S., Chertow G.M., and PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 288 (2002) 2547-2553
29. Krämer B.K., Schweda F., and Riegger G.A.J. Diuretic treatment and diuretic resistance in heart failure. Am J Med 106 (1999) 90-96
30. Neuberg G.W., Miller A.B., O'Connor C.M., et al., PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
31. Philbin E.F., Cotto M., Rocco Jr. T.A., and Jenkins P.L. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 80 (1997) 519-522
32. Bongartz L.G., Cramer M.J., Doevendans P.A., Joles J.A., and Braam B. The severe cardiorenal syndrome: 'Guyton revisited.'. Eur Heart J 26 (2005) 11-17
33. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9 (2004) 195-201
34. Boerrigter G., and Burnett Jr. J.C. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep 1 (2004) 113-120
35. Shankar S.S., and Brater D.C. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284 (2003) F11-F21
36. Brater D.C. Diuretic therapy in congestive heart failure. Congest Heart Fail 6 (2000) 197-201
37. Ravnan S.L., Ravnan M.C., and Deedwania P.C. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail 8 (2002) 80-85
38. Iyengar S., and Abraham W.T. Diuretic resistance in heart failure. Curr Heart Fail Rep 3 (2006) 41-45
39. Bourge R.C., and Tallaj J.A. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 46 (2005) 2052-2053
40. Clark W.R., Paganini E., Weinstein D., Bartlett R., Sheinfeld G., and Ronco C. Extracorporeal ultrafiltration for acute exacerbations of chronic heart failure: report from the Acute Dialysis Quality Initiative. Int J Artif Organs 28 (2005) 466-476
41. Bart B.A., Boyle A., Bank A.J., et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) Trial. J Am Coll Cardiol 46 (2005) 2043-2046
42. Costanzo M.R., Saltzberg M., O'Sullivan J., and Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 46 (2005) 2047-2051
43. Jaski B.E., Ha J., Denys B.G., Lamba S., Trupp R.J., and Abraham W.T. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 9 (2003) 227-231
44. Costanzo MR. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) [ACC.06 smaller trial late-breaking clinical trials II]. Presented at the 55th Annual Scientific Sessions of the American College of Cardiology; March 11-14, 2006; Atlanta, Georgia. Available at: http://acc06online.acc.org/Lectures.aspx?sessionId=24&date=14. Accessed June 21, 2006.
45. Marenzi G., Lauri G., Grazi M., Assanelli E., Campodonico J., and Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38 (2001) 963-968
46. Rimondini A., Cipolla C.M., Della Bella P., et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med 83 (1987) 43-48
47. Ramos R., Salem B.I., DePawlikowski M.P., et al. Outcome predictors of ultrafiltration in patients with refractory congestive heart failure and renal failure. Angiology 47 (1996) 447-454
48. Cuffe M.S., Califf R.M., Adams K.F.J., et al., Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
49. O'Connor C.M., Gattis W.A., Uretsky B.F., et al., FIRST Investigators. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 pt 1 (1999) 78-86
50. Elkayam U., Tasissa G., Binanay C., et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. Circulation 110 suppl 3 (2004) III-515 Abstract 2415
51. Abraham W.T., Adams K.F., Fonarow G.C., et al., ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 (2005) 57-64
52. Bennett S.J., Huster G.A., Baker S.L., et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 7 (1998) 168-174
53. Friedman M.M. Older adults' symptoms and their duration before hospitalization for heart failure. Heart Lung 26 (1997) 169-176
54. Steimle A.E., Stevenson L.W., Chelimsky-Fallick C., et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 96 (1997) 1165-1172
55. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
56. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
57. Khot U.N., Novaro G.M., Popovic Z.B., et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348 (2003) 1756-1763
58. Elkayam U., Kulick D., McIntosh N., Roth A., Hsueh W., and Rahimtoola S.H. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 76 (1987) 577-584
59. Larsen A.I., Goransson L., Aarsland T., Tamby J.F., and Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 134 (1997) 435-441
60. Elkayam U., Akhter M.W., Singh H., Khan S., and Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 93 (2004) 237-240
61. Adams K.F.J., Mathur V.S., and Gheorghiade M. B-type natriuretic peptide: from bench to bedside. Am Heart J 145 suppl (2003) S34-S46
62. Burger A.J. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 11 (2005) 30-38
63. Holmes S.J., Espiner E.A., Richards A.M., Yandle T.G., and Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 76 (1993) 91-96
64. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
65. Protter A.A., Wallace A.M., Ferraris V.A., and Weishaar R.E. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 9 (1996) 432-436
66. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109 (2004) 1680-1685
67. Mills R.M., LeJemtel T.H., Horton D.P., et al., Natrecor Study Group. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 34 (1999) 155-162
68. Colucci W.S., Elkayam U., Horton D.P., et al., Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
69. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
70. Peacock W.F., Holland R., Gyarmathy R., et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med 29 (2005) 243-252
71. Saltzberg M.T. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure. Rev Cardiovasc Med 5 suppl 4 (2004) S17-S27
72. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
73. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
74. Gheorghiade M., Gattis W.A., O'Connor C.M., et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
75. Ukkonen H., Saraste M., Akkila J., et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68 (2000) 522-531
76. Moiseyev V.S., Põder P., Andrejevs N., et al., RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
77. Follath F., Cleland J.G., Just H., et al., Steering Committee and Investigators of the Levosimendan infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
78. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation 112 (2005) 3363
79. Mebazaa A. The SURVIVE-W Trial: comparison of dobutamine and levosimendan on survival in acute decompensated heart failure. Circulation 112 (2005) 3364